Please ensure Javascript is enabled for purposes of website accessibility

Search

17,895 Results for "null"
  • There has been plenty of action in emerging markets recently, but today’s strong rally pushed the Cabot Emerging Markets Timer to a clear buy signal. Part of this may be the continuing effect of a great Singles’ Day splurge in China, and I write about that. We’re making some adjustments to the portfolio to put the spotlight on the winners and switch out of one laggard.
  • Today’s recommendation is a chain restaurant—a chain I’d never even heard of—but the company is growing fast and the chart is very constructive.
  • In tonight’s issue, we dive into some education, revealing a long-term chart pattern that bodes well (including one stock that’s at the top of our Watch List now). We also give you all our latest thoughts on the market and our recommended stocks, and present the usual crop of new ideas if you have some cash on the sideline.
  • Today’s recommended stock is an old-world company in a prosaic business, and its prospects are bright as it reaps improved efficiencies from its recent big merger.
  • We’ve pared back during the past few days in the Model Portfolio, but we\'re not sticking our heads in the sand and are giving our profitable stocks room to consolidate. In tonight’s issue, we dive into our game plan for our remaining stocks, and we also do some sector analysis, including two areas that are launching new leaders.
  • Market Gauge is 8Current Market Outlook


    After a straight-up move in recent weeks, the major indexes had a couple of wobbles during the past few days, which has done some damage to certain areas—small-cap indexes are standing right on top of their 50-day lines and many individual stocks and sectors have come back down to earth, even among large-cap stocks. Even so, the vast majority of major indexes and Top Ten stocks are still acting well, with more than a few racing up the charts following positive earnings reactions. We have our eyes open should the weak broad market “infect” leading stocks, but so far, the market’s recent rest looks normal to us. Thus, you should stick with a bullish stance, giving your strong stocks a chance to continue advancing, while looking for entry points as stocks pause.

    This week’s list has something for everyone, with some healthcare, some energy (for the first time in a while) and some true growth stocks. Our Top Pick is Planet Fitness (PLNT), a great cookie-cutter story that just surged on earnings. Buying on some weakness is your best bet.
    Stock NamePriceBuy RangeLoss Limit
    AbbVie Inc. (ABBV) 93.5392-9586-88
    Alnylam Pharmaceuticals (ALNY) 143.58129-134117-119
    Continental Resources (CLR) 66.1943-45.539.5-41.5
    Micron Technology, Inc. (MU) 43.3143-4539.5-40.5
    NVIDIA Corporation (NVDA) 242.42205-213188-192
    Planet Fitness (PLNT) 0.0028.5-30.526.5-27.5
    ProPetro (PUMP) 23.3015.8-16.814.5-15
    Red Hat (RHT) 0.00120-124111-113
    ZTO Express (ZTO) 28.8416.1-17.214.5-15
    Zendesk (ZEN) 82.1933-3530.5-32

  • Market Gauge is 8Current Market Outlook


    The market’s not all peaches and cream, as many sectors have been doing more gyrating than advancing, the broad market is iffy and the number of stocks hitting new highs has been falling on each push higher. But we always place most of our emphasis on the primary evidence—the trend of the major indexes and the action of leading stocks—and on that front, the evidence is clearly positive, so we remain heavily invested. The goal from here is to simply follow the system—hold on to your strong performers (though taking partial profits here or there is fine), honor your stops with any stocks that hit potholes and look for new leaders that show explosive strength.

    This week’s list is again heavy on recent earnings winners, though it has more of a small- and mid-cap flavor to it. Our Top Pick is Splunk (SPLK), a leading Big Data software firm that has gotten going after a long consolidation.

    Scheduling Note: Due to the Thanksgiving holiday, there will be no Movers & Shakers this Friday or Top Ten issue next Monday (one of our two scheduled weeks off all year). Have a great holiday weekend!

    Stock NamePriceBuy RangeLoss Limit
    Bluebird Bio (BLUE) 0.00153-161137-141
    Canada Goose Holdings (GOOS) 46.2124.5-2622-23
    Cypress Semiconductor (CY) 0.0026-1715-15.5
    ICU Medical (ICUI) 0.00202-207188-192
    Nutanix (NTNX) 55.9128.5-3025-26
    Red Rock Resorts (RRR) 34.7027-2825-25.5
    RH Inc. (RH) 252.9396-10186-90
    Splunk (SPLK) 207.6778-8271.5-73.5
    Westlake Chemical Corp. (WLK) 0.0090-9384-86
    Wingstop (WING) 121.5237-3934.5-35.5

  • A few of our stocks have been taking a breather, but the Cabot Emerging Markets Timer remains resolutely positive. Investors have remained optimistic despite a truckload of negative news and the fundamentals are solid for the stocks in the portfolio. I also have an overlooked Indian stock to recommend that ties in with the recent improvement in commodity prices.
  • In tonight’s issue we write about one stock that’s at the top of our Watch List, as well as the value of letting a stock make decisions for you. We also give you our latest thoughts on the market, our stocks and some new ideas.
  • We’re trimming our portfolio a little further, and adding a healthy new financial stock to the Dividend Growth Tier.
  • While U.S. indexes have been choppy-to-down during the past few weeks, emerging market stocks remain in good shape and our Emerging Markets Timer is positive. Our new recommendation tonight looks like one of the best ways to play the general boom in electric vehicle production in the years ahead.
  • Today’s stock is a name you’ll know. The company was born in the early days of the internet and today it’s all grown up—a major player in the world of financial transactions.
  • Today’s recommendation is a fast-growing mass market stock that has the leading market share in the online food ordering business. The stock has been trading sideways for five weeks and I think it’s ready for a breakout.
  • Today’s candidate provides at-home health care solutions to people with vascular disease. These are often chronic conditions, which account for up to 80% of every healthcare dollar spent in the U.S. The company is growing quickly, with average annual growth since 2013 is over 30%!